Abrégé

The invention relates to multispecific polypeptides comprising a first protein for the prevention, treatment or detection of a neurological disorder in the central nervous system, a second protein binding specifically to a protein expressed on the blood brain barrier, wherein the protein expressed on the brain blood barrier mediates enhanced uptake of compounds over the BBB, and a third protein binding specifically to a protein in the CNS.

Classes IPC  ?

• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes

Abrégé

The present invention relates to the field of microbial self-assembling protein fibrils as novel bionanomaterials. More specifically, the present invention relates to protein nanofibril materials comprising Bacillus endospore appendage (ENA) proteins, which are spontaneously folding helix hairpin subunits assembling into alpha-helical multimeric (A-ENA) fibrils with a hydrophobic core and covalently connected by one or more isopeptidic bonds, providing for a nanofibril of high stability and tensile strength. The invention further relates to said protein nanofibrils which are engineered or modified to provide for functionalized bionanomaterials. In particular, the invention relates to methods for recombinant production of said self-assembling protein nanofibrils, and their use in modifying bacterial endospores and endospore activity or pathogenicity.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
• C07K 14/32 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Bacillus (G)
• C12N 1/20 - BactériesLeurs milieux de culture
• C12R 1/07 - Bacillus

Abrégé

The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses means and methods for single molecule protein sequencing and/or amino add identification using cleavage inducing agent. Said cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the kinetics of said reaction.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p. ex. thromboplastine, aminopeptidase de la leucine (3.4)
• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine

Abrégé

The invention relates to the field of CAR-T cell immunotherapy, more specifically the invention relates to production and uses of glyco-engineered CAR-T cells for the improvement of immunotherapy compositions for treatment of cancer, more specifically of solid tumors. The invention specifically relates to human CAR-T cells with a mutated MGAT5 gene, as to provide for surface glycan structures devoid of tetra-antennary N-glycans, which results in a sustained memory when applied in immunotherapy, to cure cancer, reduce (recurrent) tumor growth and tumor burden, as well as to prevent relapse. The invention further relates to methods for manufacturing of those CAR-T cells, wherein addition of low amounts of DMSO during activation and expansion ex vivo skews T cell populations to a more predominant memory phenotype, thereby providing for improved glycol-engineered CAR-T cell compositions for adoptive T cell transfer.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 9/10 - Transférases (2.)
• C12N 9/22 - Ribonucléases
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome

Abrégé

The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires

Abrégé

Provided is a method of characterising a polynucleotide using a transmembrane pore, wherein the pore is a double pore comprising a first Csg G pore, or a homologue thereof, and second CsgG pore, or a homologue thereof.

Classes IPC  ?

• C07K 14/245 - Escherichia (G)
• C12Q 1/6869 - Méthodes de séquençage
• G01N 27/447 - Systèmes utilisant l'électrophorèse
• G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide

Abrégé

The present invention provides co-crystals of the anaplastic lymphoma kinase (ALK) and its ligand ALKAL2 and the related leukocyte tyrosine kinase (LTK) and its ligand ALKAL1. The invention also provides computer-assisted and other methods for selecting molecules able to modulate the interaction between ALK, LTK and their respective ligands.

Classes IPC  ?

• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
• G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire

Abrégé

Current application relates to the field of neurodegenerative diseases. Specifically, the present invention relates to screening methods to identify therapeutic candidates for the prevention and/or treatment of Alzheimer's disease. More particularly, said candidates overcome endolysosomal dysfunction resulting from an accumulation of APP-carboxyterminal fragments.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/84 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des composés inorganiques ou le pH
• G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol

Abrégé

The present invention relates to the field of tissue regeneration, particularly the field of skin lesions such as wounds, more particularly chronic wounds. The invention provides wound healing compositions. Specifically, the invention provides molecules targeting the Slc7a11 transporter such as antibodies, shRNA, siRNA, locked nucleic acids, peptide nucleic acids and morpholinos for use to treat chronic wounds such as for example diabetic wounds.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 38/46 - Hydrolases (3)
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

The invention relates to the field of predicting (clinical) response of a cancer patient to a therapy comprising an immune checkpoint blocker or to therapy with an immune checkpoint blocker. In particular enriched pre-therapy levels of intra-tumoral CD8 Temra cells and/or intra-tumoral CXCL10-positive macrophages are markers indicative of a positive response. An alternative pre-therapy marker indicative of a positive response relies on detecting enhanced levels of T cell receptor sharing between intra-tumoral and peripheral CD8 Temra cells. The invention therefore refers to methods of e.g. selecting a patient eligible for therapy comprising an immune checkpoint blocker or for therapy with an immune checkpoint blocker including determining the levels of these markers.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention belongs to the field of immunology and relates to proteins and polypeptides comprising an immunoglobulin single variable domain (ISVD) fused with a cytokine. In particular, the present invention provides a chimeric protein which comprises an immunoglobulin single variable domain (ISVD) fused with a cytokine, wherein an internal fusion site of the ISVD is linked to the cytokine, wherein the internal fusion site is located in a loop or turn between two secondary structure elements. The fusion of the cytokine to the ISVD upon binding to the cytokine receptor or receptor subunit(s) allows for the modulation of the cytokine receptor activity and/or downstream signaling.

Classes IPC  ?

• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• C07K 14/52 - CytokinesLymphokinesInterférons
• C07K 14/55 - IL-2
• C07K 14/56 - IFN-alpha
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C07K 14/54 - Interleukines [IL]

Abrégé

Acinetobacter baumanniiA. baumanniiAcinetobacter baumanniiAcinetobacter baumannii infection.

Classes IPC  ?

• C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• A61P 31/04 - Agents antibactériens

Abrégé

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• C07D 217/04 - Composés hétérocycliques contenant les systèmes cycliques de l'isoquinoléine ou de l'isoquinoléine hydrogénée avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle contenant l'azoteAlkylène-bis-isoquinoléines avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués liés à l'atome d'azote du cycle
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.

Classes IPC  ?

• C07D 513/14 - Systèmes condensés en ortho
• A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
• A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
• A61K 31/5383 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes hétérocycliques
• A61K 31/542 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes hétérocycliques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• C07D 241/42 - Benzopyrazines avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
• C07D 241/44 - Benzopyrazines avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone de l'hétérocycle
• C07D 241/50 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques avec des hétéro-atomes liés directement aux atomes d'azote du cycle
• C07D 265/36 - Oxazines-1, 4Oxazines-1, 4 hydrogénées condensés avec des carbocycles condensés avec un cycle à six chaînons
• C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
• C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 471/04 - Systèmes condensés en ortho
• C07D 471/14 - Systèmes condensés en ortho
• C07D 487/04 - Systèmes condensés en ortho
• C07D 487/14 - Systèmes condensés en ortho
• C07D 498/04 - Systèmes condensés en ortho
• C07D 513/04 - Systèmes condensés en ortho

Abrégé

The present invention relates to the field of antibody-drug-conjugates (ADCs) and the application of glyco-engineering strategies in a novel site-specific conjugation technology. The invention particularly relates to ADCs wherein a drug entity is conjugated an aminooxy-functionalized linker at di- or trisaccharide N-glycans in the hinge region, and methods for producing the same. More particularly, said conjugate is obtained through oxidized galactose- or sialyl-groups obtained from glyco-engineered eukaryotic cells which produce antibodies with an N-glycan structure that is limited to a shortened Asn- GlcNac-Gal(-Sia) branch in the hinge region of the antibody.

Classes IPC  ?

• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs

Produits et services

Pharmaceutical preparations and substances; Medical preparations and substances; Veterinary preparations; Biological preparations for pharmaceutical, medical and veterinary use; Diagnostic and therapeutic preparations for pharmaceutical, medical and veterinary purposes; Preparations and substances for use in drug discovery. Science and technology services, namely, scientific and technological research in the field of pharmaceuticals, medical science, biotechnology, biomedicine, veterinary science and industrial biotechnology; natural science services, namely, scientific and medical research; clinical research in the fields of cardiovascular diseases, allergies, immune and inflammatory diseases, metabolic diseases, cancer, diseases of the central nervous system, and infectious diseases; clinical research in the fields of medical and biotechnological procedures, namely, radiology, chemotherapy and in vivo imaging; medical laboratories; conducting evaluations in the field of new pharmaceuticals; consultancy relating to pharmaceutical research and development; drug discovery services; drug design; research and development in the field of biotechnology; providing a web hosting platform for biotechnological research.

Produits et services

(Based on 44(d) Priority Application) Pharmaceutical preparations and substances, namely, pharmaceutical preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions and symptoms related to metabolism, allergies, (auto)immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Pharmaceutical preparations and substances, namely, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, (auto)immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; (Based on Intent To Use) ; Medical preparations and substances, namely, fungal preparations in the nature of fungal medications for medical purposes, probiotic preparations for medical use, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies,(auto)immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Veterinary preparations in the nature of veterinary pharmaceutical preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, (auto)immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Biologicals preparations for pharmaceutical, medical and veterinary use, namely, biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, (auto)immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Diagnostic and therapeutic preparations for pharmaceutical, medical and veterinary purposes, namely, diagnostic preparations for veterinary and medical use, pharmaceutical preparations and biological preparations for the treatment, mitigation, diagnosis, or prevention of diseases, conditions, and symptoms related to metabolism, allergies, immune and inflammatory diseases, infectious diseases, the cardiovascular system, the pulmonary system, the respiratory system, oncology, dermatology, the gastrointestinal system, topical illnesses, neurology, endocrinology, the urological system, the reproductive system, nutritional needs, ophthalmic system, renal system, blood and blood-related disorders, integumentary and lymphatic systems in humans and animals; Preparations and substances for use in drug discovery, namely, preparations for growing cells or for producing biologicals for medical, pharmaceutical, and veterinary purposes, and reagents and media for medical, pharmaceutical and veterinary diagnostic purposes, namely, media and reagents serving as inoculate, clinical medical reagents, and diagnostic reagents Science and technology services, namely, scientific and technological research in the field of pharmaceuticals, medical science, biotechnology, biomedicine, veterinary science and industrial biotechnology; Manufacturing of biological preparations; natural science services, namely, scientific and medical research; clinical research in the fields of cardiovascular diseases, allergies, immune and inflammatory diseases, metabolic diseases, cancer, diseases of the central nervous system, and infectious diseases; clinical research in the fields of medical and biotechnological procedures, namely, radiology, chemotherapy and in vivo imaging; medical laboratories; conducting evaluations in the field of new pharmaceuticals; consultancy relating to pharmaceutical research and development; drug discovery services; Drug design; research and development in the field of biotechnology; providing a web hosting platform for biotechnological research

Abrégé

The present invention relates to the field of sustainable agriculture. In particular, the present invention relates to isolated Bradyrhizobium bacteria having enhanced characteristics, including but not limited to enhanced adaptation to the low and medium root zone temperature for example in North-West Europe.

Classes IPC  ?

• C12N 1/20 - BactériesLeurs milieux de culture
• A01H 3/00 - Procédés de modification des phénotypes
• A01N 63/20 - BactériesSubstances produites par des bactéries ou obtenues à partir de celles-ci

Abrégé

The present invention relates to the field of microbial growth, more specifically microbial overgrowth, even more specifically overgrowth of Enterobacteriaceae, specifically under conditions of apoptosis in the gut such as IBD, colitis, chemotherapy and food borne bacterial infections. The present invention provides inhibitors of a bacterial target, pyruvate formate lyase, which can be used to regulate the overgrowth of Enterobacteriacea.

Classes IPC  ?

• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 31/04 - Agents antibactériens

Abrégé

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.

Classes IPC  ?

• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.

Classes IPC  ?

• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
• A61K 31/33 - Composés hétérocycliques

Abrégé

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.

Classes IPC  ?

• C07D 215/02 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle
• A61K 31/47 - QuinoléinesIsoquinoléines
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.

Abrégé

The present invention relates to the field of disorders of the central and peripheral nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that short peptides derived from the soluble amyloid precursor protein α (sAPPα) bind and modulate GABABR1a. The peptides are provided for clinical use, more particularly for the treatment of neurological diseases such as CMT as well as for psychiatric disorders.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The disclosure relates to the compounds selectively inhibiting Solute Carrier Family 4 member 4/ Electrogenic Sodium Bicarbonate Cotransporter 1 (SLC4A4/NBCe1). More in particular, said compounds are SLC4A4/NBCe1-inhibiting single domain antibodies, compounds comprising at least one CDR polypeptide of a SLC4A4/NBCe1-inhibiting single domain antibody, and compounds comprising a SLC4A4/NBCe1-inhibiting single domain antibody. Applications of compounds inhibiting SLC4A4/NBCe1 are likewise included.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The invention relates to combinations of Alzheimer disease risk loci, more in particular short genetic variant loci (SGVs). Combinations of such SGVs were identified that are significantly and synergistically pathogenic. Applications of these combinations, such as diagnostic applications, are included as well.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The disclosure relates to maize plants with altered characteristics including tolerance to abiotic stress such as drought and/or increased water use efficiency, along with methods of using and making the same.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• A01H 1/06 - Procédés de mutation, p. ex. traitements par produits chimiques ou irradiations
• A01H 3/00 - Procédés de modification des phénotypes
• A01H 6/46 - Gramineae ou Poaceae, p. ex. ivraie, riz, blé ou maïs
• C12N 5/14 - Cellules végétales

Abrégé

The present invention relates to cultivated crops which have increased yield as well as compositions and methods for increasing yield.

Classes IPC  ?

• A01H 1/00 - Procédés de modification des génotypes
• C12N 9/22 - Ribonucléases

Abrégé

The invention relates to methods of breast tumor analysis relying on the detection of expression levels of specific genes. Such methods find application in, amongst other, predicting the response of a breast cancer patient to immunotherapy or to immunogenic therapy, and in following up such responses. The expression levels of the genes can thus be used in determining which breast cancer patients are most likely to respond to immunotherapy or immunogenic therapy. The genes serving as biomarkers are individually highly performant in predicting the response of a breast tumor to immunotherapy or to immunogenic therapy, but are weak in predicting the response of melanoma to immunotherapy or to immunogenic therapy. Diagnostic kits are likewise part of the invention.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates to antibodies or antibody fragments binding to the human and non-humane primate transferrin receptor. The antibodies herein described can be used as agents to deliver pharmaceutical compounds in or across cells in the process of receptor mediated endocytosis and/or transcytosis. As the transferrin receptor is also present at the blood brain barrier endothelial cells, one aspect of the invention provides means and methods to increase the delivery of pharmaceutical compounds to the central nervous system.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor (CI-M6PR), more specifically polypeptide agents comprising an immunoglobulin single variable domain (ISVD) specifically binding CI-M6PR at nano- to picomolar affinity, fused to further protein binding agents specifically binding extracellularly-accessible protein targets, such as membrane proteins, extracellular or secreted proteins. More specifically said CI-M6PR-specific ISVD recognizes CI-M6PR N-terminal domains 1, 2 and/or 3, thereby providing for means and methods for internalization, lysosomal targeting and degradation of agents comprising said ISVD, and of targets bound to said protein binding agents. The CI-M6PR binders disclosed herein are thus linked or fused to a further protein binding agent, in particular another antigen-binding protein, such as an ISVD or antibody, relevant for use in therapy, more specifically for treatment of diseases affected by said target antigen bound by said antigen-binding protein. More specifically disclosed herein are CI-M6PR ISVD fusions to antigen-binding proteins specifically binding EGFR, for treatment of cancer.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/46 - Immunoglobulines hybrides

Abrégé

The present invention relates to the field of plant molecular biology, more particularly to the field of agriculture, even more particularly to the field of improving the yield of plants. The present invention provides chimeric genes and constructs which can be used to enhance the yield in plants and crops.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux

Abrégé

The present invention relates to the field of yeast fermentations. More particularly, the invention relates to mutant alleles useful to engineer industrially relevant traits in yeast.

Classes IPC  ?

• C12N 1/18 - Levure de boulangerieLevure de bière
• A61K 36/064 - Saccharomycetales, p. ex. levure de boulanger
• C12N 9/22 - Ribonucléases
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
• C12P 7/16 - Butanols
• C12P 7/54 - Acide acétique
• C12R 1/865 - Saccharomyces cerevisiae

Abrégé

The present invention relates to the field of glycoproteomics for identifying novel cell surface O-linked glycopeptide epitopes. The invention relates to methods for identifying O-linked glycopeptides, more specifically Tn- or SiaTn-antigen O-glycosylation sites on cell surface proteins, said method comprising a combined workflow of enzymatic treatments of cells or tissue samples to allow specific enrichment and labelling of Tn antigens, followed by mapping of the O-glycopeptides through LC-MS/MS. More specifically, the invention relates to a chemo-enzymatic method to produce labelled O-glycan-peptides from a plasmamembrane-protein extract sample, wherein Sialyltransferase (ST3Gal1/ST3Gal3) treatment is used to protect free galactose against a follow-on treatment with Galactose oxidase, wherein the oxidized glycans are simultaneously labelled. The invention further relates to a tandem mass spectrometry method using an enriched TMT-labelled (Sia)Tn-antigen glycopeptides in a dual fragmentation triggered approach to resolve the identity, localisation and quantification of the O-linked glycan peptides.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates to the field of agriculture, even more particularly to the field of increasing the root length and root biomass of plants including also hairy root biomass. The present invention provides chimeric genes and constructs which can be used to increase the root size of crops, to increase the yield of crops and to increase the biomass of hairy roots.

Classes IPC  ?

• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

The present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions, such as wounds. The invention provides topical plasters and wound healing compositions. Specifically, the invention provides hydrogels compositions of glycyrrhizinic acid analogues. The compositions and methods of the invention are useful especially for assisting the process of wound healing, particularly chronic open lesions that are slow to heal or resistant to healing.

Classes IPC  ?

• A61L 26/00 - Aspects chimiques des bandages liquides ou utilisation de matériaux pour les bandages liquides
• A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires

Abrégé

Capnocytophaga canimorsusCapnocytophaga canimorsusCapnocytophaga canimorsus GH29 enzyme. The invention further specifies methods and uses of said enzymes and compositions for production of defucosylated Fc-containing proteins and their therapeutic utility.

Classes IPC  ?

• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• C12P 19/14 - Préparation de composés contenant des radicaux saccharide préparés par action d'une carbohydrase, p. ex. par action de l'alpha-amylase
• C12P 21/00 - Préparation de peptides ou de protéines

Abrégé

The present invention relates to the field of plant genetic engineering, particularly the modulation of gene expression in plant cells for improved regeneration competence. The invention discloses means and methods wherein the Ethylene Response Factor (ERF) and Phytochrome A Signal Transduction 1 (PAT1) transcription factor complex activity in plant cells grants increased regeneration.

Classes IPC  ?

• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
• C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The invention relates to regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors such as antisense oligonucleotides. In particular, these synaptogyrin-3 inhibitors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques

Abrégé

The disclosure relates to a novel method for selection and identification of specific polypeptide binding agents for a target of interest. More specifically, the selection method involves capturing the target of interest on a surface using a first binding agent to form an immobilized antigen complex, selecting for specific antigen-binding polypeptides present in a sample, preferably as a display library, and eluting the target protein and the selective polypeptide binder, using a second binding agent competing for the target binding site of the first binding agent. More specifically, the selection method presented herein provides for an efficient and highly selective medium- to high-throughput technology applicable to recombinant antibody libraries, including immune and unbiased or proteome-wide display libraries, wherein selections can be performed without a need for purified target protein, in physiological conditions.

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN

Abrégé

The invention relates to identification of regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors such as siRNA molecules. The synaptogyrin-3 inhibitors disclosed herein are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies in particular.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice

Abrégé

PhascolarctobacteriumVeillonellaEubacteriumAgathobacterLactiplantibacillusAnaerostipesAnaerostipes. Aspects and embodiments described herein may be used in the treatment of joint inflammation, symptoms thereof, and underlying diseases and conditions.

Classes IPC  ?

• A61K 35/74 - Bactéries
• A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
• C12N 1/20 - BactériesLeurs milieux de culture
• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61K 31/365 - Lactones
• A61K 31/415 - 1,2-Diazoles
• A61K 31/42 - Oxazoles
• A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C12R 1/01 - Bactéries ou actinomycètes
• C12R 1/25 - Lactobacillus plantarum

Abrégé

The invention relates to field of neurodegeneration, more particularly to Tau neurotoxicity. The application identifies genes whose reduced expression suppresses pathological Tau mediated effects. These Tau suppressors are provided for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies in particular.

Classes IPC  ?

• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

The invention relates to polypeptides, in particular polypeptides comprising an immunoglobulin domain, binding to human and cynomolgus CD8b protein and to applications of such polypeptides such as for use as diagnostic agent, for example as an immunotracer.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The invention relates to protecting regulatory T cells (Tregs) against dysfunctionality as caused in e.g. the auto-immune disease setting. In particular, such protection is warranted in case of adoptive transfer or Tregs as a means of treatment of auto-immune and other diseases, and as a means of controlling transplant or graft rejection. Furthermore in particular, the protection is enabled by inhibiting the Treg mitochondrial sodium/lithium/calcium exchanger.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

The invention relates to polypeptides, in particular polypeptides comprising an immunoglobulin domain, binding to human and murine CD163 protein and to applications of such polypeptides such as for use as diagnostic agent, for example as an immunotracer. The invention further relates to conjugates, in particular conjugates of polypeptides comprising an immunoglobulin domain binding to human and murine CD163 protein and a further moiety, such as a therapeutic moiety, and to applications of such conjugates.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention provides novel agrochemicals and formulations thereof and the use of these agrochemical formulations for providing abiotic stress tolerance, such as cold and frost tolerance, in plants.

Classes IPC  ?

• A01N 43/38 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à cinq chaînons condensés avec des carbocycles
• A01N 47/30 - Dérivés contenant le groupe N—CO—N—aryle ou N—CS—N—aryle
• A01N 43/707 - Triazines-1,2,3 ou -1,2,4Triazines-1,2,3 ou -1,2,4 hydrogénées
• A01P 21/00 - Régulateurs de croissance des végétaux

Abrégé

Compositions and binding agents specifically binding the Spike protein of Corona viruses via at least two different binding sites and potently neutralizing coronaviruses, in particular sarbecoviruses, such as SARS-COV-1 and SARS-COV-2. The compositions or agents specifically bind to epitopes of the Receptor binding domain (RBD) of the Spike protein wherein both epitopes are conserved over multiple clades of the sarbecoviruses, providing broadly neutralizing pan-specific antibody-based compositions, thereby reducing viral escape. Application and uses of these agents and compositions are disclosed.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes

Abrégé

Disclosed herein are yeast strains and derivatives thereof. as well as compositions comprising the yeast strains for use in ethanol manufacture. The disclosure also relates to processes for producing ethanol from biomass using the yeast strains and compositions. In particular, the yeast strains produce lower glycerol and higher ethanol, and have a higher temperature tolerance and higher fermentation rate than strains and products currently used in ethanol production processes.

Classes IPC  ?

• C12P 7/10 - Éthanol en tant que produit chimique et non en tant que boisson alcoolique préparé comme sous-produit, ou préparé à partir d'un substrat constitué par des déchets ou par des matières cellulosiques d'un substrat constitué par des matières cellulosiques
• C12N 1/18 - Levure de boulangerieLevure de bière
• C12R 1/865 - Saccharomyces cerevisiae

Abrégé

The present methods and systems generally relate to the biomedical field and relate to subfields of computational biology and bioinformatics. More, specifically the invention provides an artificial intelligence algorithm which can predict the stability of proteins and protein complexes.

Classes IPC  ?

• G16B 15/20 - Repliement de protéines ou de domaines

Abrégé

The invention relates to the field of sustainable agriculture, more particularly to means and methods to protect crops against cold and chilling stress. The application provides three novel Flavobacterium strains that upon administration to plants, protect the plants against growth retardation induced by low temperatures.

Classes IPC  ?

• A01H 3/00 - Procédés de modification des phénotypes
• A01N 63/20 - BactériesSubstances produites par des bactéries ou obtenues à partir de celles-ci
• C12N 1/20 - BactériesLeurs milieux de culture

Abrégé

The present invention relates to the field of structural biology. More specifically, the present invention relates to novel antigen-binding chimeric proteins, their uses and methods in three-dimensional structural analysis of macromolecules, such as X-ray crystallography and high-resolution Cryo-EM, and their use as a therapeutic, diagnostic, or imaging tool. Even more specifically, the invention relates to a fusion of a scaffold protein and an antigen-binding domain wherein the scaffold protein of said fusion interrupts the Immunoglobulin domain topology to form a rigid chimer.

Classes IPC  ?

• C07K 16/46 - Immunoglobulines hybrides
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C07K 14/195 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• G01N 23/20 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la diffraction de la radiation par les matériaux, p. ex. pour rechercher la structure cristallineRecherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la diffusion de la radiation par les matériaux, p. ex. pour rechercher les matériaux non cristallinsRecherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la réflexion de la radiation par les matériaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Produits et services

Investment funds; Financing and funding services; Private equity fund investment services; Management of private equity funds; Venture capital.

Abrégé

The present invention is generally related to a method and system for droplet manipulation and more specifically to a method and system for droplet manipulation using electrowetting technology. The methods and systems herein described are of particular interest for analyzing cell to cell interactions, more particularly for screening for immune cell-mediated cell lysis of tumor cells.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes

Abrégé

The present invention relates to the field of microbiology, in particular to the field of bacterial antibiotic resistance. more particularly to the field of resistance to beta-lactam inhibitors. The invention provides non-natural compounds which induce the aggregation of beta-lactamases, particularly beta-lactamases of class A. In addition, the invention provides combination therapies and pharmaceutical compositions between the non-natural molecules and beta-lactam antibiotics.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 31/43 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes
• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention provides vaccines and compositions, methods and uses of immunogenic vaccine compositions for eliciting an immune response to members of trypanosomatids such as Trypanosoma brucei, T. cruzi and Leishmania species.

Classes IPC  ?

• A61K 39/005 - Antigènes de Trypanosoma
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/002 - Antigènes de protozoaires
• A61K 39/008 - Antigènes de Leishmania
• A61P 37/04 - Immunostimulants

Abrégé

The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• C07K 14/555 - Interférons [IFN]

Abrégé

The present invention relates to novel pore monomers, pores formed from the pore monomers and their uses in analyte detection and characterisation.

Classes IPC  ?

• C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
• C12Q 1/6869 - Méthodes de séquençage
• G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide

Abrégé

The invention relates to the application of inhibition of SLC4A4 (Solute Carrier Family 4 member 4) in the treatment of cancer. This either as monotherapy (such as for treating cancer refractive or poorly responding to immunotherapy) or as combination therapy in conjunction with an immunotherapeutic compound (such as for treating cancers poorly responding or refractive to immunotherapy). In particular, inhibition of SLC4A4 is capable of restoring response to immunotherapy such as immune checkpoint inhibitor therapy.

Classes IPC  ?

• A61K 31/26 - Esters d'acide cyanique ou isocyaniqueEsters d'acide thiocyanique ou isothiocyanique
• A61K 38/46 - Hydrolases (3)
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

This disclosure relates to methods of determining the loss of heterozygosity (LOH) status of a tumor and to methods of determining the homologous recombination repair deficiency (HRD) status of a tumor. Such methods further translate into ways of predicting the response of a subject having cancer to treatments or therapies comprising DNA damaging agents and/or agents inhibiting or impairing DNA repair; and into use of such treatments or therapies when the LOH or HRD status of the subject having cancer is positive.

Classes IPC  ?

• G16B 20/10 - Ploïdie ou détection du nombre de copies
• G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs

Abrégé

The present invention relates to the field of bacterial protein engineering and protein fibers applicable as metal-binding bionanomaterials. More specifically, the present invention relates to engineered bacterial endospore appendage (Ena) proteins modified to contain metal-binding polypeptide (MBP) inserts providing for stable, flexible and robust protein assemblies with metal-binding activity. In particular, the invention relates to methods for designing Ena-fusion proteins capable of self-assembling into fibers, and for recombinant production of said self-assembling Ena-MBP fusion protein subunits, assemblies and fibers, ensuring a sustainable source of biological material for use in metal mineralization, metal sequestration, and metal-removal applications such as waste water treatment, water softening, or bioremediation.

Classes IPC  ?

• C07K 14/32 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Bacillus (G)
• C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
• B09C 1/10 - Régénération de sols pollués par des procédés microbiologiques ou utilisant des enzymes
• C02F 1/44 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par dialyse, osmose ou osmose inverse
• C02F 3/34 - Traitement biologique de l'eau, des eaux résiduaires ou des eaux d'égout caractérisé par les micro-organismes utilisés

Abrégé

The invention relates to antigen-binding protein agents specifically binding the hemagglutinin- neuraminidase (HN) protein of human parainfluenza virus 3 (hPIV-3), with cross-reactivity for Sendai Virus (SeV) as well as human parainfluenza virus serotype 1 (hPIV-1) HN, resulting in a cross-neutralizing binding protein to act as a protection agent against parainfluenza infection and/or disease caused by such an infection. More specifically, the invention relates to a family of immunoglobulin single variable domains (ISVDs) capable of broadly blocking HN neuraminidase activity, thereby providing for a novel hPIV-1/-3 cross-neutralizing antiviral protein binding agent. The invention further relates to the use of said antigen-binding proteins in prevention or treatment of acute respiratory tract infections, croup, pneumonia, and exacerbations of chronic obstructive pulmonary disease.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

The invention relates to the field of genetic engineering and synthetic biology, more particularly to means and methods for facilitating genetic recombination. The application discloses novel Cre recombinase dependent recombination sites that supports a simultaneous cloning and testing approach.

Classes IPC  ?

• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
• C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
• C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus

Abrégé

Agents that bind to sarbecoviruses of multiple clades, neutralizing sarbecovirus infection, in particular neutralizing SARS-CoV-1 and SARS-CoV-2 infection. The agents bind to a unique epitope of the sarbecovirus ACE2-receptor binding domain (RBD) but do not inhibit binding of ACE2 with the RBD. Applications and uses of these agents are further disclosed.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/72 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des hormones
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• G01N 23/20 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la diffraction de la radiation par les matériaux, p. ex. pour rechercher la structure cristallineRecherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la diffusion de la radiation par les matériaux, p. ex. pour rechercher les matériaux non cristallinsRecherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la réflexion de la radiation par les matériaux
• G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand

Abrégé

This document relates to methods and materials for treating congenital disorders of glycosylation (CDG; e.g., a phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG)). For example, this document provides methods and materials for using (a) one or more aldose reductase (AR) inhibitors (e.g., epalrestat) and (b) one or more nucleosides to treat a mammal having one or more CDG (e.g., PMM2-CDG).

Classes IPC  ?

• A61K 31/426 - 1,3-Thiazoles
• A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61K 31/33 - Composés hétérocycliques
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire

Abrégé

The present invention relates to the field of time-resolved protein sampling, more specifically for use in structural biology, even more specifically for structural analysis of proteins by Cryogenic-electron microscopy (Cryo-EM). The invention provides for methods and devices for preparing vitrified samples for transmission electron microscopy at millisecond time-resolution using a microfluidics-based integrated device. More specifically, the sampling means and methods combine fast mixing with a tunable droplet-on-demand generation to control droplet formation, spraying and sampling velocity, resulting in a sampling method requiring very limited protein amounts.

Classes IPC  ?

• G01N 1/42 - Traitement à basse température des échantillons, p. ex. cryofixation
• G01N 1/28 - Préparation d'échantillons pour l'analyse

Abrégé

The present invention provides novel chimeric genes for the production of quillaic acid and derivatives thereof in eukaryotic cells such as yeasts and plants.

Classes IPC  ?

• C12N 9/02 - Oxydoréductases (1.), p. ex. luciférase
• C12N 9/90 - Isomérases (5.)
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

The present invention relates to human CCR8 (hCCR8) binders, wherein the hCCR8 binder is cross-reactive with a non-human primate CCR8. Such binders are particularly useful for the depletion of intra-tumoural regulatory T-cells and immunotherapy in general.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The application concerns a novel hominid-specific pathway to modulate neuronal excitability. In a first aspect, the application relates to a modulator of the interaction between a LRRC37B protein and the NAV1.6 voltage-gated sodium channel for use as a medicine. Furthermore, means and methods are provided to treat neurological disorders characterized by affected neuron excitability. In further aspects, the invention relates to methods for identification of or for screening for modulators of neuronal excitability.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61P 25/08 - AntiépileptiquesAnticonvulsivants
• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to human CCR8 (hCCR8) binders, wherein the hCCR8 binder is cross-reactive with murine CCR8. Such binders are particularly useful for the depletion of intra-tumoural regulatory T-cells and immunotherapy in general.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to human CCR8 (hCCR8) binders, wherein the hCCR8 binder is a non-blocking binder of hCCR8. Such binders are particularly useful for the depletion of intra-tumoural regulatory T-cells and immunotherapy in general tumour

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to the field of glycoprotein production means and methods. More specifically, the present invention provides for a novel yeast strain with a mutant Och1 gene resulting in modified N-glycosylation properties of said strain. Even more specifically, said mutant Och1 gene comprises a sequence coding for a mutant OCH1 protein in which one amino acid near the catalytic site, corresponding to position 151 of the OCH1 protein of the methylotrophic wild type Pichia pastorisstrain, is deleted. More specifically, the use of said mutant yeast strain for recombinant expression of glycoproteins results in more homogenous mammalian-like N-glycan structures on said heterologously produced glycoproteins.

Classes IPC  ?

• C12N 9/10 - Transférases (2.)
• C12P 21/00 - Préparation de peptides ou de protéines
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)

Abrégé

The invention relates to the application of inhibition of transcription factor 4 (TCF4/ITF2) in the treatment of cancer. This in particular in combination therapy in conjunction with an immunotherapeutic compound (such as for treating cancers poorly responding or refractive to immunotherapy). In particular, inhibition of TCF4/ITF2 is capable of restoring response to immunotherapy such as immune checkpoint inhibitor therapy. Expression levels of TCF4/ITF2 as well as levels of mesenchymal-like cancer cells in a cancer lesion are predictive of future response to immunotherapy early after initiation of the immunotherapy. Further part of the invention are methods of detecting mesenchymal-like cancer cells.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to the field of human genetics, more specifically to treatments for a disease or condition associated with an abnormal processing of the Amyloid Precursor Protein (APP), preferably familiar Alzheimer disease (FAD). The invention in particular relates to antisense oligonucleotides (AONs) that can be used for treating such diseases or conditions.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• A61P 35/00 - Agents anticancéreux
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 38/19 - CytokinesLymphokinesInterférons
• A61K 38/21 - Interférons
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 14/525 - Facteur de nécrose de tumeurs [TNF]
• C07K 14/56 - IFN-alpha
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention provides binding molecules, particularly antibodies which bind to the IL-12RP2. The antibodies are able to bring about the killing of cells expressing IL-12R02 on their surface. The invention further relates to pharmaceutical compositions comprising the binding molecules. The binding molecules and pharmaceutical compositions of the invention may be used in therapy and diagnosis. They may be employed to deplete cells expressing IL-12Rp2. As IL-12R[32 is expressed narrowly, predominately on 'type 1 immune cells' such as CD4+ Thl, CD8+ Tel, and 1LC1 cells in autoimmune and inflammatory conditions, the binding molecules of the invention may be used to treat and prevent such conditions via such cell depletion.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention provides binding molecules, particularly antibodies which bind to the IL-12Rβ2 and gp 130 subunits of the IL-35 receptor (IL-35R). The binding molecules are preferably able to act as agonists of the IL-35R. The invention further relates to pharmaceutical compositions comprising the binding molecules. The binding molecules and pharmaceutical compositions of the invention may be used in therapy and diagnosis. They may be employed to treat or prevent autoimmune and inflammatory conditions.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 37/02 - Immunomodulateurs
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

The present invention relates to the field of affinity purification and provides for means and methods applying protein binding agents competing for a target protein for use as capture and elution tool, wherein the elution agent comprises an immunoglobulin single variable domain (ISVD), and is capable of displacing the capturing binding agent. More specifically, the displacement efficiency of the ISVD-containing protein binding agent is driven by its dissociation kinetics, with a rate constant of dissociation (koff) equal or lower as compared to the capturing agent. Furthermore, said protein binding agents are deployable in high-throughput purification from complex mixtures, or for capturing protein-complexes, thereby facilitating structural, biochemical and physicochemical analysis of said target proteins.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 1/34 - PurificationNettoyage

Abrégé

The present invention relates to novel compounds of formula (Ia), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to processes for the preparation of said compounds. The present invention relates to novel compounds of formula (Ia), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to processes for the preparation of said compounds.

Classes IPC  ?

• C07D 215/38 - Atomes d'azote
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 471/04 - Systèmes condensés en ortho
• C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 215/12 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec des radicaux hydrocarbonés substitués liés aux atomes de carbone du cycle
• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique

Abrégé

The present invention relates to a combination comprising a Treg depletor and an LTBR agonist. Such a combination is particularly useful for use in the treatment of a cancer.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 471/04 - Systèmes condensés en ortho
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to binding agents specifically binding to the folate transport complex. More specifically, antibodies or antibody fragments including immunoglobulin single variable domain (ISVD) antibodies are disclosed that bind the human folate receptor alpha (hFOLRα) present at the choroid plexus epithelial cells. The invention further relates to the antibodies and the methods herein described for use to increase the delivery of pharmaceutical compounds to the central nervous system via the process of receptor mediated endocytosis and/or transcytosis.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments

Abrégé

The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux

Abrégé

The current invention relates to an improved microfluidic device for protein/protein complex purification, as well as an associated methodology and system. In particular it relates to systems and methods for electron microscopy, preferably cryogenic electron microscopy (cryo-EM), on protein samples, comprising: a. at least one microfluidic chip with inlet and outlet and purification device; b. at least one illumination means and detection means for, preferably fluorescence, measurements on the microfluidic chip; c. a pumping system adapted for operable connection to the microfluidic chip, and configured for controlling flow in the operably connected microfluidic chip; d. a microscopy grid, preferably a cryogenic electron microscopy (cryo-EM) grid, for holding fluid samples; e. preferably a cryogenic container, for a cryogenic coolant; f. preferably a transport system for moving the cryo-EM grid between a position for receiving a fluid sample from the microfluidic chip and the cryogenic container; g. a control system, preferably a processor, which receives information on the measurements from the detection means, configured for controlling the pumping system at least based on said information, and further configured for controlling the illumination and detection means and preferably also for controlling the transport system.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• C07K 1/14 - ExtractionSéparationPurification
• H01J 37/20 - Moyens de support ou de mise en position de l'objet ou du matériauMoyens de réglage de diaphragmes ou de lentilles associées au support
• C07K 1/16 - ExtractionSéparationPurification par chromatographie
• G01N 1/42 - Traitement à basse température des échantillons, p. ex. cryofixation
• G01N 23/2202 - Préparation d’échantillons à cet effet

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
• C07K 1/14 - ExtractionSéparationPurification
• C07K 1/16 - ExtractionSéparationPurification par chromatographie
• G01N 1/42 - Traitement à basse température des échantillons, p. ex. cryofixation
• G01N 23/2202 - Préparation d’échantillons à cet effet
• H01J 37/20 - Moyens de support ou de mise en position de l'objet ou du matériauMoyens de réglage de diaphragmes ou de lentilles associées au support

Abrégé

The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present disclosure furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to processes for the preparation of said compounds.

Classes IPC  ?

• C07D 215/06 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle comportant uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés à l'atome d'azote du cycle
• C07D 239/82 - Atomes d'oxygène avec un radical aryle lié en position 4
• A61P 35/00 - Agents anticancéreux

Abrégé

SarbecovirusSarbecovirusSarbecovirusSarbecovirus, more particularly to a quaternary epitope located within 2 adjacent HR2 domains. The invention also relates to methods using these binding agents and uses thereof.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

This invention relates to Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-CoV-2, including SARS-CoV-2 variants, and SARS-CoV-1. The binding agents, in particular the antibodies and antibody fragments, bind to heptad repeat 2 (HR2) domain of spike protein of the Sarbecovirus, more particularly to a quaternary epitope located within 2 adjacent HR2 domains. The invention also relates to methods using these binding agents and uses thereof.

Classes IPC  ?

• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN

Abrégé

The disclosure relates to the field of the human gut microbiome, more particularly, to its effect on health and disease. Provided herein are means and methods to diagnose and treat or reduce the severity of gut flora dysbiosis as well as of gastro-intestinal inflammation and inflammation-associated disorders or conditions in a subject in need thereof.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The invention is situated in the field of cancer treatment. In particular it relates to treatments comprising combining an inhibitor of the pyrimidinergic receptor P2Y6 and an immune checkpoint inhibitor. Further in particular, the treatment is of benefit for cancers poorly responding to immune checkpoint inhibitor therapy.

Classes IPC  ?

• A61K 31/26 - Esters d'acide cyanique ou isocyaniqueEsters d'acide thiocyanique ou isothiocyanique
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a method and composition for prevention and treatment of infections in a subject, in particular with intracellular bacteria. The invention provides an optimized intracellular delivery of an active agent, in particular a nucleic acid, using a nanoparticle formulation including an iNKT cell agonist.

Classes IPC  ?

• A61K 39/02 - Antigènes bactériens
• A61P 31/04 - Agents antibactériens
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The invention relates to binding agents for targeted protein degradation comprising an Alphabody protein molecule specifically targeting an intracellular protein, and a degrader molecule acting as scavenger of proteasomal activity. Said Alphabody protein-based degrader binding agent forms a ternary complex with the target protein and the E3 ligase in the cell, resulting in activation of targeted protein degradation. Particularly, the binding agent thus comprises cell-penetrating Alphabody proteins linked to a degrader moiety. More particularly, the invention relates to binding agents which are hybrid molecules wherein the degrader moiety is conjugated to the Alphabody protein. More particularly, the invention relates to binding agents comprising degrader moieties specifically binding an E3 ligase complex to enhance ubiquitination and proteasomal degradation of the target specifically binding the Alphabody protein. Most particularly, the invention relates to binding agents comprising MCL1- and MDM4/MDM2-targeting Alphabody-based degrader molecules for use in treatment of diseases associated with said target molecules, preferably for use in treatment of cancer.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• A61P 35/00 - Agents anticancéreux
• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes

Abrégé

The present invention relates to a combination comprising an oncolytic virus and an LTBR agonist. The LTBR agonist may be administered separately or may be encoded by the oncolytic virus. Such a combination is particularly useful for use in the treatment of a cancer.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/86 - Vecteurs viraux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to an adenine base editor (ABE), and components thereof. The present invention also relates to a complex comprising an adenine base editor (ABE) and a guide RNA in a functionally associated form. The present invention further relates to a nucleic acid molecule encoding the ABE/guide RNA, an expression construct or a vector comprising a nucleic acid sequence encoding the adenine base editor and/or the nucleic acid sequence encoding the guide RNA. The present invention further relates to a cell comprising an adenine base editor (ABE) and a method of adenine base editing of a target site in a genome of interest in at least one cell of a prokaryotic organism, including bacterial and archaeal organisms, or eukaryotic organism. Besides that, the present invention relates to various methods, kits and uses associated with the ABEs provided.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C12N 9/78 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5)
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

The present invention relates to an adenine base editor (ABE), and components thereof. The present invention also relates to a complex comprising an adenine base editor (ABE) and a guide RNA in a functionally associated form. The present invention further relates to a nucleic acid molecule encoding the ABE/guide RNA, an expression construct or a vector comprising a nucleic acid sequence encoding the adenine base editor and/or the nucleic acid sequence encoding the guide RNA. The present invention further relates to a cell comprising an adenine base editor (ABE) and a method of adenine base editing of a target site in a genome of interest in at least one cell of a prokaryotic organism, including bacterial and archaeal organisms, or eukaryotic organism. Besides that, the present invention relates to various methods, kits and uses associated with the ABEs provided.

Classes IPC  ?

• C12N 9/22 - Ribonucléases
• C12N 9/78 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5)
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

The present invention relates, in part, to vaccine compositions, adjuvants, chimeric proteins, or chimeric protein complexes and their use as vaccines or therapeutic agents. The present invention further relates to methods of vaccination or treatment of various diseases.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/12 - Antigènes viraux
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Aspects of the invention concern non-naturally occurring molecules capable of downregulating the amount or biological activity specifically of mutant or variant forms of a protein, as well applications thereof.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61P 35/00 - Agents anticancéreux
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by mutant forms of soluble agents that are part of the chimeric proteins. Pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C07K 14/525 - Facteur de nécrose de tumeurs [TNF]
• C07K 14/505 - Érythropoïétine [EPO]
• C07K 14/52 - CytokinesLymphokinesInterférons
• A61P 35/00 - Agents anticancéreux
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion